Targeting IL-33 in COPD: Who Benefits and What Remains Unknown

Medical experts are exploring IL-33-targeted therapy as a potential treatment for a broader range of COPD patients. Current biologics are limited to those with high eosinophil counts, but IL-33 pathways may offer a more inclusive therapeutic option.
Why it matters
Expanding treatment options for COPD could significantly improve quality of life for the majority of patients currently ineligible for existing biologic therapies.
Interleukin-33 (IL-33)-targeted therapy could extend biologic treatment to most patients with COPD, as opposed to the eosinophil-defined minority eligible for current agents, according to Francesca Polverino, MD, PhD, Lester and Sue Smith Professor of Medicine at Baylor College of Medicine.1
Polverino discussed the potential reach of IL-33 blockade and the unresolved questions surrounding its biology in an interview with the editorial team at HCPLive at the time of the GOLD 2026 COPD International Conference held in Philadelphia.1
Which Patients with COPD Could Benefit From Targeting IL-33?
Available COPD biologics have been limited to patients with elevated blood eosinophil counts, Polverino said. Some clinicians use a threshold of 150 cells/µL, but the most compelling data support counts above 300 cells/µL.2
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in